Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.06 USD | +0.68% | +1.05% | -14.73% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.73% | 2.5B | |
+39.98% | 54.04B | |
+45.26% | 41.96B | |
-1.46% | 41.92B | |
-7.20% | 28.35B | |
+12.35% | 26.35B | |
-21.31% | 19B | |
+7.27% | 13B | |
+28.28% | 12.28B | |
+25.96% | 12.19B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Oppenheimer Slashes Price Target on Intellia Therapeutics to $70 From $80, Maintains Outperform Rating